syncope/癲癇性発作

Long QT syndrome (LQTS) is an ion channelopathy which occurs in approximately 1 in every 2500 individuals. Symptoms include; syncope, seizures and sudden cardiac death (SCD). LQTS's genetic defects culminate in delayed cardiac repolarization identified on a 12 lead electrocardiogram (ECG) as a

Background: Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) are the two major compounds found in the cannabis plant. Reports from patients, families, and the scientific community suggest that CBD (when used as an add-on therapy) decreases the number of convulsive seizures in children and adults

The study drug used in this research study is perampanel, an FDA approved medication for the treatment of seizures. The study is being done to examine whether the study drug affects the following non-invasive tests of brain activity: electroencephalogram (EEG), visual evoked potential (VEP),

The purpose of this study is to conduct a comparison in patients' cardiac function, ECG, and pacemakers' threshold value, time limit and so on among dual chamber pacemaker and HBP. The clinic trial is about to conduct pacemaker implantation in 84 participants, which distribute into dual chamber

The purpose of this study is to conduct a comparison in patients' cardiac function, ECG, and pacemakers' threshold value, time limit and so on among dual chamber pacemaker, and HBP. The clinic trial is about to conduct pacemaker implantation in 84 participants, which distribute into dual chamber

Epilepsy affects 50 million people of all ages. It is the most common neurologic disorder across the lifespan, and has been found to be associated with an increased risk of mortality compared to the general population. EEG is an important tool in the diagnostic work-up of patients with suspected

The clinical diagnosis of dilated cardiomyopathy is made from history, physical examination, and noninvasive testing. The initial clinical manifestations of dilated heart failure are generally those of respiratory distress secondary to congestion of the pulmonary and systemic venous

Unclear transient loss of consciousness is a frequent interdisciplinary diagnostic problem. Of particular importance is the distinction between epileptic and non-epileptic events. Our group showed in two previous studies that serum lactate is elevated in epileptic seizures, but mostly not in

The patients of this prospective study were selected from a sample of patients who were admitted to the emergency room of the University Hospital RWTH Aachen with an unclear impairment of consciousness. Only patients who later on were diagnosed as having experienced a GTCS or a syncope and whose

Study Procedures Once the subject has agreed to participate in the study and has signed the consent form, the baseline visit can be performed. A full medical history will be taken and a physical exam will be done as per local routine practice for an embolization procedure. The Cognard scale will be

The overall goals are to determine whether patients with epilepsy who have the highest risk of SUDEP have an underlying genetic cardiovascular disorder. The investigators are seeking patients with epilepsy who have a high risk of SUDEP identified by using a risk scoring tool called SUDEP-7 and/or

Our primary outcome is to assess the safety of Dotarem in these patients up to 24 hours after Dotarem injection. The patients will be monitored in the hospital for at least 2 hours following the completion of the MRI exam. Many of these patients will have received sedation for the MRI and would be

1. INTRODUCTION AND RATIONALE The live attenuated Bacillus Calmette-Guerin (BCG) vaccine protects against extrapulmonary infection with Mycobacterium tuberculosis and against leprosy [1, 2]. It has been shown that vaccination with BCG also leads to non-specific protective effects: early

This multi-center study will consist of two parts: Part A and Part B. Part A will investigate the dose-ranging pharmacokinetics and tolerability of GWP42003-P. Part B is a 1:1 randomized, placebo-controlled 60 day comparison of GWP42003-P against placebo, at the dose which has been identified by